GF CSI HK Innovative Drugs Industry ETF(QDII)

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

NMPA Officially Releases 'Implementation Measures for Drug Trial Data Protection'

Chan: HK Has 4 Advantages to Become Core of Medical Innovation Ecosystem, Regulatory Center to Launch This Year

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

Innovent Biologics to Present Phase 3 Trial Results of Mazdutide at 2026 ADA Scientific Sessions

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

Jade Pharmaceutical's SYS6010 Enters Phase 3 Clinical Trials for Esophageal Squamous Cell Carcinoma

513120

RemeGen acknowledged a delay in disclosing purchases of SPDB wealth management products due to an internal oversight regarding compliance with Hong Kong listing rules. The company plans to implement remedial measures, including improved internal controls, enhanced cross-department reviews, staff training, and consultation with external advisers to prevent future issues.

PUBT

REMEGEN

RemeGen

SPD Bank

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

RemeGen says SPDB wealth product disclosure delay stems from oversight, sets remedial steps

159615

513700

520880

159506

159316

520690

159892

HBM Holdings repurchased 500,000 ordinary shares on May 19, 2026, at prices ranging from HKD 12.06 to HKD 12.54 per share, totaling HKD 6,154,480. The shares will be held as treasury shares.

China Southern Hang Seng Biotech ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

HBM HOLDINGS-B

HBM Holdings files HKEX disclosure, repurchases shares at HKD 12.31 each

512290

159837

159992

159849

159570

United Laboratories has received clearance from China's NMPA to begin clinical trials for its innovative drug TUL108, a broad-spectrum beta-lactamase inhibitor aimed at treating bacterial infections. The drug will be tested in combination with meropenem against drug-resistant pathogens. The U.S. FDA had previously approved the investigational new drug application for TUL108 on January 28, 2026.

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Huaan Hang Seng Biotech ETF

ChinaAMC SSE STAR Biology and Medicine ETF

UNITED LAB

United Labs says China regulator clears TUL108 injection for clinical trial

01801

516930

510660

516500

512010

589720

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

prnewswire

INNOVENT BIO

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

TransThera Sciences (Nanjing), Inc. is raising HK$156 million through a placement of 3,836,000 new H shares at HK$40.83 each, an 18% discount to market prices. This represents 1.24% of its existing H-share capital and aims to broaden the shareholder base despite modest dilution for current holders. The transaction is subject to regulatory approvals and may not complete, posing execution risks as the company seeks capital for operations and strategic plans.

Tip Ranks

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

TRANSTHERA-B

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

09995

688331

RemeGen Co. Ltd. plans to amend its articles of association to increase registered capital and total issued A shares due to its 2022 and 2023 Restricted A Share Incentive Schemes. The company will also update internal governance documents to enhance compliance and internal controls, with changes to be approved at the 2025 annual general meeting. This move aims to align governance with regulatory guidelines and improve oversight of board operations and executive pay.

Bosera Hang Seng Health Care ETF(QDII)

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

02268

WXXWY

02269

ARKG

Earendil Labs has announced the successful dosing of the first cohort in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). This antibody shows high affinity and blocks TSLP receptor interactions, demonstrating potent activity in preclinical studies. The company aims to develop innovative treatments for various immunological disorders, emphasizing their commitment to advancing next-generation biologics therapies.

WUXI XDC

WuXi Biologics

WUXI BIO

Sanofi

iShares US Pharma

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

BlackRock, Inc.

Proshares UltraShort Nasdaq Biotech

Microbiotica reports positive results for MB097 in advanced melanoma

01833

516610

159929

CICC has initiated coverage on PA GOODDOCTORwith an Outperform rating and a target price of HKD14.2. The report highlights the company's strategic transformation in healthcare and elderly care, achieving full-year profitability in 2024 and positive operating profit in 2025. CICC expects significant profit growth driven by AI enhancements and operational efficiencies, forecasting EPS of RMB0.2 and RMB0.29 for 2026 and 2027, respectively, with a CAGR of 28.3% from 2025 to 2027.

AASTOCKS News

PA GOODDOCTOR

Dacheng CSI All Share Health Care Equipment and Services ETF

China Universal 800 Health Care ETF

CICC

CICC Initiates PA GOODDOCTOR  with Outperform Rating, TP HKD14.2

Harbour BioMed announced promising preclinical data for LET003, its first AI-enabled drug candidate targeting obesity. LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, while preserving lean mass. The results suggest LET003 could be a best-in-class therapy for obesity, achieving significant fat loss and lean mass improvement at lower doses compared to competitors. The findings were supported by the company's Hu-mAtrIx™ AI platform, indicating strong potential for future development.

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

GF CSI HK Innovative Drugs Industry ETF(QDII)(513120.SH)